The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
A Systematic Review of the Economic and Humanistic Burden of Illness in Irritable Bowel Syndrome and Chronic Constipation
Open accessAbstract
BACKGROUND: Irritable bowel syndrome (IBS) and chronic constipation (CC) are common functional gastrointestinal disorders affecting 14% and 20% of the U.S. population, respectively. Reviews of the evidence on the burden of illness associated with IBS and CC have not been comprehensive in scope and have not provided an assessment of the distribution of health care costs across categories of resource use. OBJECTIVES: To (a) identify studies from any geographic region or country perspective that measure the economic burden of the disease; (b) analyze the direct (medical, drug, and other components) and indirect costs of illness; and (c) assess published evidence of the humanistic burden as measured by quality of life (QOL). METHODS: An electronic literature search was conducted using journal databases, including MEDLINE, The Cochrane Library, EconLit, CINAHL, and Digestive Disease Week meeting abstracts. Specific search terms used were "irritable bowel syndrome" and "chronic constipation." In databases that accommodated Boolean searches, terms related to economic and quality of life outcomes were incorporated. Studies were included if they evaluated patients with an IBS or CC diagnosis and quantitatively measured the economic or humanistic burden of disease. Results were descriptively analyzed. RESULTS: The search identified a total of 882 unique publications. Thirty-five articles and abstracts met the inclusion criteria. Studies included 1,706 IBS-C, 2,264 IBS-D, 2,892 IBS-A, 15,830 IBS unclassified, and 1,278 CC patients. Nineteen of 35 studies assessed cost-of-illness endpoints, and from the U.S. perspective, the direct cost per-patient for IBS ranged from $1,562 to $7,547 per year, while direct costs of CC ranged from $1,912 to $7,522 per year. From the U.S. perspective, the indirect costs of IBS ranged from $791 to $7,737 per year, and no study assessed the indirect costs of CC. For IBS, data on the distribution of costs attributable to categories of resource use varied widely, particularly outpatient costs (12.7% to > 50% of total costs), inpatient costs (6.2% to 40.8%), and pharmacy or drug costs (5.9% to 46.6%). Comparable data on CC were not identified. Nineteen studies of IBS patients measured the humanistic burden of disease; 14 studies utilized SF-36; and within-study domain scores were significantly lower in IBS patients compared with non-IBS controls. Only 1 study of CC patients reported humanistic burden of disease. CONCLUSIONS: The studies identified in the systematic review varied in the method used to identify patients with IBS and CC. Results were not typically reported by IBS subtype. We observed a large variation in attributable direct and indirect costs and drivers of these costs. Future research should refine burden of illness estimates to subtypes so that estimates associated with IBS-C and CC are differentiated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whitehead, W. E., Palsson, O., & Jones, K. R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32392 · Cited by 1,116
The impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781
Chronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494
Gender-related differences in IBS symptoms
Lee, O. Y., Mayer, E. A., Schmulson, M., Chang, L., & Naliboff, B. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03961.x · Cited by 228
The Burden of Illness of Irritable Bowel Syndrome: Current Challenges and Hope for the Future
Hulisz, D. (2004) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2004.10.4.299 · Cited by 215
The economic impact of irritable bowel syndrome
Inadomi, J. M., Fennerty, M. B., & Bjorkman, D. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.t01-1-01736.x · Cited by 190
Pace, F., Molteni, P., Bollani, S., Sarzi‐Puttini, P., Stockbrügger, R., Porro, G. B., & Drossman, D. A. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310004524 · Cited by 157
Bowel Habit Subtypes and Temporal Patterns in Irritable Bowel Syndrome: Systematic Review
Guilera, M., Balboa, A., & Mearin, F. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40674.x · Cited by 131
Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL)
Amouretti, M., Le Pen, C., Gaudin, A.-F., Bommelaer, G., Frexinos, J., Ruszniewski, P., Poynard, T., Maurel, F., Priol, G., & El Hasnaoui, A. (2006) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(06)73160-8 · Cited by 110
Cited by
Global burden of irritable bowel syndrome: trends, predictions and risk factors
Black, C. J., & Ford, A. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0286-8 · Cited by 610
Dimidi, E., Christodoulides, S., Fragkos, K. C., Scott, S. M., & Whelan, K. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.089151 · Cited by 316
The role of mast cells in functional GI disorders
Wouters, M. M., Vicario, M., & Santos, J. (2016) · Gut · doi:10.1136/gutjnl-2015-309151 · Cited by 308
Diagnosis and Treatment of Dyssynergic Defecation
Rao, S. S. C., & Patcharatrakul, T. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16060 · Cited by 278
Sibelli, A., Chalder, T., Everitt, H., Workman, P., Windgassen, S., & Moss-Morris, R. (2016) · Psychological Medicine · doi:10.1017/s0033291716001987 · Cited by 196
Metadata
- Authors
- Nellesen, D., Yee, K., Chawla, A., Lewis, B. E., & Carson, R. T.
- Venue
- Journal of Managed Care Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2013-11
- Volume
- 19
- Issue
- 9
- Pages
- 755-764
- ISSN
- 1083-4087 (ISSN-L)
- 1944-706X
- OpenAlex
- W2148638310
- Cited by
- 242
- References
- 10
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Systematic Review of the Economic and Humanistic Burden of Illness in Irritable Bowel Syndrome and Chronic Constipation. https://app.cochat.ai/papers/10.18553/jmcp.2013.19.9.755
- The paper
- Nellesen, D., Yee, K., Chawla, A., Lewis, B. E., & Carson, R. T. (2013). A Systematic Review of the Economic and Humanistic Burden of Illness in Irritable Bowel Syndrome and Chronic Constipation. Journal of Managed Care Pharmacy. https://doi.org/10.18553/jmcp.2013.19.9.755
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.